Atea Pharmaceuticals Inc Ordinary Shares AVIR
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if AVIR is a good fit for your portfolio.
News
-
Atea Pharmaceuticals Completes Patient Enrollment in Global Phase 3 SUNRISE-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk Patients
-
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
-
Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call on February 28, 2024
Trading Information
- Previous Close Price
- $3.71
- Day Range
- $3.68–3.76
- 52-Week Range
- $2.77–5.19
- Bid/Ask
- $3.30 / $4.00
- Market Cap
- $311.41 Mil
- Volume/Avg
- 267,759 / 391,745
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 75
- Website
- https://www.ateapharma.com
Comparables
Valuation
Metric
|
AVIR
|
ENTA
|
PHAT
|
---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 0.56 | 1.69 | — |
Price/Sales | — | 4.39 | 715.95 |
Price/Cash Flow | — | — | — |
Price/Earnings
AVIR
ENTA
PHAT
Financial Strength
Metric
|
AVIR
|
ENTA
|
PHAT
|
---|---|---|---|
Quick Ratio | 17.86 | 6.04 | 9.88 |
Current Ratio | 18.24 | 6.25 | 10.25 |
Interest Coverage | — | — | −3.99 |
Quick Ratio
AVIR
ENTA
PHAT
Profitability
Metric
|
AVIR
|
ENTA
|
PHAT
|
---|---|---|---|
Return on Assets (Normalized) | −15.46% | −27.96% | −63.92% |
Return on Equity (Normalized) | −16.16% | −47.34% | — |
Return on Invested Capital (Normalized) | −19.92% | −44.45% | −206.62% |
Return on Assets
AVIR
ENTA
PHAT
Biotechnology Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Yddpnqzq | Drtg | $550.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Svzjwmw | Clczrt | $101.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Crfmddftf | Blngcys | $98.1 Bil | |
MRNA
| Moderna Inc | Bcpwmtzq | Gmpf | $39.1 Bil | |
ARGX
| argenx SE ADR | Kznxsqpz | Ndrz | $21.7 Bil | |
BNTX
| BioNTech SE ADR | Vyxbfdjs | Zbsy | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Wgkgbhlr | Pqlvxn | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Bmycszrj | Jmylzl | $17.1 Bil | |
RPRX
| Royalty Pharma PLC Class A | Vxssklzc | Cjcsq | $12.5 Bil | |
INCY
| Incyte Corp | Vwrrpcnm | Rgpcbt | $11.9 Bil |